Kanyi Maqubela

Who they are

Kanyi Maqubela is Managing Partner at Kindred Ventures — co-founded Heartbeat Health, the largest virtual heart health platform in the U.S., and littleBits, the educational electronics company later acquired by Sphero.

Person

Kanyi studied Philosophy at Stanford (before that, Phillips Academy Andover) and came up through an unusual mix of consulting, growth, and creative institutions — McKinsey, Doostang, One Block Off the Grid, and a stint as Adjunct Professor at NYU Tisch School of the Arts. He joined Kindred Ventures in 2018 as Managing Partner when the firm was still finding its footing as a seed-stage investor. Before Kindred he was a Partner at Collaborative Fund, where he sharpened his thesis around companies with broad societal impact. Alongside those employed tracks he's co-founded three companies: Heartbeat Health (the largest virtual cardiology platform in the U.S.), littleBits (educational electronics kits, later acquired by Sphero), and Primary Venture Partners (an early-stage VC firm). The through-line is a philosopher turned operator turned investor who keeps building things — he doesn't just write checks. He writes at kanyi.blog — active since 2008 — on infographics, photography, distribution strategy, and the implications of AGI, and he posts on Medium and X about venture capital, digital health, fintech, climate tech, and what technology does to civilization at scale. Most recently he was on stage at ViVE 2026 on a panel titled 'Supercharging Specialty Care' and at Startup Grind 2025 alongside Othman Laraki on AI in healthcare.

Company

Kindred Ventures closed $355 million across two new funds — Kindred Ventures IV and Kindred Selector II — in 2026, its largest raise to date. The firm was founded in 2014 by Steve Jang, with Maqubela as co-Managing Partner, and operates out of San Francisco as both a seed fund and startup studio that originates ideas and assembles founding teams. Recent portfolio activity reflects a hard lean into generative AI: the firm has backed Perplexity, Fal, Corgi, PlayAI, Quo, Inversion Space, Nuro, Rebellions, Creatify, Aalo Atomics, Mem0, and Causal Labs. Kindred positions itself as a concentrated frontier strategy — small team, big bets — focused on AI, software, and information technology.

Market

Kindred competes in the seed and pre-seed venture capital space against a large field of early-stage funds, though it differentiates through a concentrated portfolio approach and an active studio model rather than broad spray-and-pray seed investing. The generative AI wave has become the dominant organizing theme for frontier seed investors, and Kindred's 2026 fund raise and portfolio construction signal it is leaning further into that trend — particularly AI infrastructure, robotics, and frontier tech — rather than diversifying away from it.

Network

Maqubela's most visible recent collaborator is Othman Laraki, his co-panelist at Startup Grind 2025 on AI in healthcare — Laraki is a notable figure in the AI-health intersection worth noting as a warm bridge. His firm's co-founder is Steve Jang, who started Kindred Ventures in 2014. His network spans the Collaborative Fund alumni community from his prior Partner role there.

Othman Laraki· Co-panelist, Startup Grind 2025; AI/healthcare operator
Steve Jang· Co-founder and Managing Partner, Kindred Ventures

How they likely show up

Co-founded three companies (Heartbeat Health, littleBits, Primary Venture Partners) alongside investing roles → he is a builder-investor, not a passive capital allocator; he likely engages most when there's something to construct, not just evaluate.
Philosophy degree from Stanford followed by McKinsey consulting → probably comfortable with abstract frameworks but expects them to cash out in concrete decisions; won't tolerate fuzzy thinking dressed up as depth.
Active public writer since 2008 at kanyi.blog, covering everything from infographics to AGI implications → comfortable thinking in long time horizons and across domains; likely reads widely and rewards interlocutors who do too.
Adjunct Professor at NYU Tisch School of the Arts alongside operator/investor roles → suggests he values teaching and synthesis, not just doing; he probably explains his bets in narrative terms, not just data.
Content themes span VC, digital health, fintech, climate, blockchain, and AI infrastructure → a generalist investor by conviction, not convenience; he'll push back on anyone who tries to narrow him to one vertical.
Possibly — mixed tenure shape across roles suggests he moves when the learning curve flattens, not for title or salary.

Conversation tips

→ Reference a specific post from kanyi.blog — he's been writing there since 2008 and it signals you went beyond the LinkedIn profile.
→ Ask about Heartbeat Health specifically, not digital health generically — he built the thing, so he has strong operational opinions about what actually works in virtual cardiology.
→ The ViVE 2026 panel on 'Supercharging Specialty Care' is a fresh hook — if you have any view on specialty care economics or AI triage, bring it; he'll engage with a specific take.
→ Don't treat him as a pure capital allocator — he's co-founded companies and assembled founding teams through Kindred's studio model; he responds to builders, not just pitchers.

Toolbox

Openers

Open on the $355M raise for Kindred Ventures IV and Selector II — asking how the new fund size changes the firm's approach to concentration versus diversification is a specific, non-obvious question that shows you tracked the announcement.
Mention Heartbeat Health — he co-founded the largest virtual cardiology platform in the U.S. while running a VC firm; the tension between operator instincts and investor discipline is a rich entry point.
Reference the Startup Grind 2025 panel with Othman Laraki on AI in healthcare — it's his most recent named public appearance and a signal he's thinking hard about where AI actually moves the needle in clinical settings, not just the hype.

Discovery questions

You co-founded Heartbeat Health while investing full-time — how does having built a company in digital health change how you evaluate the founders pitching you in that space?
Kindred describes itself as a startup studio as well as a seed fund — when you originate an idea and assemble a founding team, how do you think about the line between co-founder and investor?
Your portfolio from the new funds includes everything from Perplexity to Aalo Atomics — what's the connective thesis that makes nuclear and AI infrastructure feel like the same bet to you?

Avoid

Don't pitch or discuss investments in broad thematic terms ('the AI opportunity is huge') — he writes publicly about civilizational-scale technology implications and will expect you to have a specific, differentiated view, not a market-size slide.

Make it yours